Literature DB >> 22887708

Passive and active targeting of quantum dots for whole-body fluorescence imaging of breast cancer xenografts.

Irina V Balalaeva1, Tatiana A Zdobnova, Irina V Krutova, Anna A Brilkina, Ekaterina N Lebedenko, Sergey M Deyev.   

Abstract

Far-red and near-infrared fluorescent quantum dots (QDs) have become advancing contrast agents for efficient whole-body tumor imaging. In this study, we investigated the possibility of the vital fluorescence imaging of tumor using two contrast agents on the basis of QDs: bioinert QDs coated with polyethyleneglycol and QDs bound with anti-HER2/neu scFv antibodies. HER2/neu-positive breast cancer tumor xenografts in nude mice were used as a model. It was shown that both bioinert and tumor-targeted QD probes can be successfully applied for visualization of the tumor using in vivo imaging method, but fluorescent signal of QD-4D5scFv in tumors was considerably stronger than that of QD-PEG.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22887708     DOI: 10.1002/jbio.201200080

Source DB:  PubMed          Journal:  J Biophotonics        ISSN: 1864-063X            Impact factor:   3.207


  13 in total

Review 1.  Inorganic nanoparticles in diagnosis and treatment of breast cancer.

Authors:  Cristina Núñez; Sergio Vázquez Estévez; María Del Pilar Chantada
Journal:  J Biol Inorg Chem       Date:  2018-02-16       Impact factor: 3.358

Review 2.  Quantum dots-based tissue and in vivo imaging in breast cancer researches: current status and future perspectives.

Authors:  Lin-Wei Wang; Chun-Wei Peng; Chuang Chen; Yan Li
Journal:  Breast Cancer Res Treat       Date:  2015-04-02       Impact factor: 4.872

3.  Bioreactor-Based Tumor Tissue Engineering.

Authors:  A E Guller; P N Grebenyuk; A B Shekhter; A V Zvyagin; S M Deyev
Journal:  Acta Naturae       Date:  2016 Jul-Sep       Impact factor: 1.845

Review 4.  Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems.

Authors:  Janel Kydd; Rahul Jadia; Praveena Velpurisiva; Aniket Gad; Shailee Paliwal; Prakash Rai
Journal:  Pharmaceutics       Date:  2017-10-14       Impact factor: 6.321

5.  Antibody fragments as nanoparticle targeting ligands: a step in the right direction.

Authors:  Daniel A Richards; Antoine Maruani; Vijay Chudasama
Journal:  Chem Sci       Date:  2016-09-16       Impact factor: 9.825

Review 6.  Recent advances in "smart" delivery systems for extended drug release in cancer therapy.

Authors:  Regina-Veronicka Kalaydina; Komal Bajwa; Bessi Qorri; Alexandria Decarlo; Myron R Szewczuk
Journal:  Int J Nanomedicine       Date:  2018-08-20

Review 7.  Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.

Authors:  M F Fiordelisi; L Auletta; L Meomartino; L Basso; G Fatone; M Salvatore; M Mancini; A Greco
Journal:  Contrast Media Mol Imaging       Date:  2019-09-22       Impact factor: 3.161

8.  Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors.

Authors:  E A Sokolova; O A Stremovskiy; T A Zdobnova; I V Balalaeva; S M Deyev
Journal:  Acta Naturae       Date:  2015 Oct-Dec       Impact factor: 1.845

9.  HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.

Authors:  Evgeniya Sokolova; Evgeniy Guryev; Andrey Yudintsev; Vladimir Vodeneev; Sergey Deyev; Irina Balalaeva
Journal:  Oncotarget       Date:  2017-03-28

Review 10.  New Frontiers in Diagnosis and Therapy of Circulating Tumor Markers in Cerebrospinal Fluid In Vitro and In Vivo.

Authors:  Olga A Sindeeva; Roman A Verkhovskii; Mustafa Sarimollaoglu; Galina A Afanaseva; Alexander S Fedonnikov; Evgeny Yu Osintsev; Elena N Kurochkina; Dmitry A Gorin; Sergey M Deyev; Vladimir P Zharov; Ekaterina I Galanzha
Journal:  Cells       Date:  2019-10-02       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.